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Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes
The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial
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Charlton Wilson, MD,# Mario Stylianou, PHD,* Wm. James Howard, MD**
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Rapid City, South Dakota; and Washington, DC
Objectives This secondary analysis from the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial examines the effects of
lowering low-density lipoprotein cholesterol (LDL-C) with statins alone versus statins plus ezetimibe on common ca-
rotid artery intima-media thickness (CIMT) in patients with type 2 diabetes and no prior cardiovascular event.
Background It is unknown whether the addition of ezetimibe to statin therapy affects subclinical atherosclerosis.
Methods Within an aggressive group (target LDL-C 70 mg/dl; non–high-density lipoprotein cholesterol 100 mg/dl;
systolic blood pressure 115 mm Hg), change in CIMT over 36 months was compared in diabetic individuals
40 years of age receiving statins plus ezetimibe versus statins alone. The CIMT changes in both aggressive
subgroups were compared with changes in the standard subgroups (target LDL-C 100 mg/dl; non–high-density
lipoprotein cholesterol 130 mg/dl; systolic blood pressure 130 mm Hg).
Results Mean (95% confidence intervals) LDL-C was reduced by 31 (23 to 37) mg/dl and 32 (27 to 38) mg/dl in the
aggressive group receiving statins plus ezetimibe and statins alone, respectively, compared with changes of 1
(3 to 6) mg/dl in the standard group (p  0.0001) versus both aggressive subgroups. Within the aggressive
group, mean CIMT at 36 months regressed from baseline similarly in the ezetimibe (0.025 [0.05 to 0.003]
mm) and nonezetimibe subgroups (0.012 [0.03 to 0.008] mm) but progressed in the standard treatment
arm (0.039 [0.02 to 0.06] mm), intergroup p  0.0001.
Conclusions Reducing LDL-C to aggressive targets resulted in similar regression of CIMT in patients who attained equivalent
LDL-C reductions from a statin alone or statin plus ezetimibe. Common carotid artery IMT increased in those
achieving standard targets. (Stop Atherosclerosis in Native Diabetics Study [SANDS]; NCT00047424) (J Am
Coll Cardiol 2008;52:2198–205) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.031a
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nhibiting the Niemann-Pick–like 1 enterocyte receptor,
hereby up-regulating low-density lipoprotein cholesterol
LDL-C) receptors and lowering serum levels of LDL-C
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December 16/23, 2008:2198–205 Ezetimibe in Type 2 Diabetesesultant lowering will translate into a reduction in clinical
therosclerotic cardiovascular (CV) events, similar to that
bserved with statins. This hypothesis, however, remains
nproven.
No data are available on the influence of ezetimibe on
therosclerosis except for findings from the ENHANCE
Effect of Combination Ezetimibe and High-Dose Simva-
tatin Versus Simvastatin Alone on the Atherosclerotic
rocess in Subjects With Heterozygous Familial Hypercho-
esterolemia) trial (3). Despite an additional 17% reduction
n LDL-C in the group receiving ezetimibe plus simvastatin
ompared with LDL-C levels in the statin alone group, the
verage increase in common carotid artery intima-media
hickness (CIMT) over 2 years in the group receiving
ombination therapy did not differ significantly from that in
he statin-only group (3).
See page 2206
The SANDS (Stop Atherosclerosis in Native Diabetics
tudy) trial was a randomized, open-label, blinded to
utcomes, 3-year trial that examined the effects of aggressive
oals for LDL-C (70 mg/dl), non–HDL-C (100 mg/
l), and blood pressure (BP) (115/75 mm Hg) reduction
ersus standard goals of 100 mg/dl, 130 mg/dl, and
130/80 mm Hg, respectively, in 499 individuals with type
diabetes (4). The primary outcome was change in CIMT
fter 36 months of treatment. Substantial epidemiological
ata document strong relationships among LDL-C, non–
DL-C, BP, and CV events in American Indians, a
opulation with high rates of diabetes and diabetes-related
V disease (5,6). Among patients randomized to the
ggressive treatment goals (n  252), ezetimibe was used in
bout one-third as an adjunct to statin therapy. This
econdary analysis from SANDS examines the effect of
ggressive lowering of LDL-C and non–HDL-C with
tatins alone versus statins plus ezetimibe on CIMT and
ther measures of carotid atherosclerosis. Individuals ran-
omized to standard LDL-C, non–HDL-C, and systolic
lood pressure (SBP) targets served as a reference group.
ethods
ecruitment and intervention. Details of the design and
ain results of SANDS have been published (4,7). In total,
99 American Indian men and women 40 years of age
ith type 2 diabetes, LDL-C 100 mg/dl, SBP 130 mm
g, and no prior CV events were enrolled between May
003 and July 2004 at 4 clinical centers and randomized to
ggressive (n  252) or standard treatment groups (n 
47), stratified by center and gender (Fig. 1). All partici-
ants provided informed written consent. The study was
pproved by all participating institutional review boards, the
ational Institutes of Health, and all participating Ameri-an Indian communities. aThe standard group was treated
o conventional goals for LDL-C
100 mg/dl), non–HDL-C (130
g/dl), and SBP (130 mm Hg),
nd the aggressive group to goals
f 70 mg/dl, 100 mg/dl, and 115
m Hg, respectively. The algo-
ithm for attaining lipid goals was
ased on recommendations of the
ational Cholesterol Education
rogram–Adult Treatment Panel
II (8). If lifestyle modification was
nsuccessful in lowering LDL-C
o the prescribed goals within 3
onths, a statin was started. If the
DL-C goal was not reached with a statin alone, ezetimibe
as added. Non–HDL-C goals were addressed using fish oil,
enofibrate, or niacin. Details of the intervention procedures
nd targets have been published (4,7). The baseline visit
ncluded collection of demographic data, health history, and
urrent medication use plus a physical exam, electrocardio-
ram, carotid artery ultrasound, and echocardiogram. Height,
eight, waist circumference, and seated BP were measured;
asting blood samples were collected to measure chemistry
anel, lipoprotein profile, glucose, hemoglobin A1c, C-reactive
rotein, and creatinine; and urine samples were obtained for
rinary albumin and creatinine as described previously (4,7).
articipants were followed from date of entry until death, loss
o follow-up, request for no further contact, or completion of
he study, regardless of adherence to the medication interven-
ion. Follow-up visits occurred in both groups after 1 month
nd then every 3 months through 36 months, and a lipid
rofile was obtained using a Cholestech LDX apparatus
Cholestech Corporation, Hayward, California) standardized
gainst the laboratory assay (9,10). At 36 months, fasting blood
nd urine samples were obtained to repeat all baseline mea-
urements; additionally, fasting blood samples for complete
ipoprotein profile and urine samples for albumin and creati-
ine were obtained at 6, 12, 18, 24, and 30 months (4,7).
utcomes ascertainment. At baseline and 18- and 36-
onth visits, carotid ultrasound studies were performed
ollowing standardized protocols (11) by centrally trained
onographers and interpreted at a core reading center by a
ingle experienced cardiologist reader blinded to treatment
ssignment (12). For these studies, B-mode imaging from
ultiple angles was performed to determine the presence
nd location of plaque (focal protrusion into the vessel
umen 50% greater than the surrounding wall), as well as
rterial wall dimensions. Plaque score (0 to 8) was deter-
ined as the number of arterial segments (left and right
ommon carotid, bulb, internal and external carotid arteries)
ontaining plaque; a participant with plaque was anyone
ith a score 1. End-diastolic B-mode images of the distal
ight and left common carotid artery were acquired in real
ime, and a 1-cm segment of each far wall was measured using
Abbreviations
and Acronyms
BP  blood pressure
CIMT  common carotid
artery intima-media
thickness
CV  cardiovascular
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
SBP  systolic blood
pressuren automated system employing an edge detection algorithm
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Ezetimibe in Type 2 Diabetes December 16/23, 2008:2198–205ith manual override capacity. One hundred separate dimen-
ional measurements were obtained from the 1-cm segment
nd averaged to obtain mean CIMT and lumen diameter.
ata analysis. This non–pre-specified secondary analysis
ompared CIMT changes in those receiving: 1) aggressive
ipid therapy with statin monotherapy; 2) aggressive therapy
ith statin plus ezetimibe; or 3) standard statin mono-
herapy. Of 499 participants, 47 individuals in whom
IMT measurements were not available after 36 months of
reatment were excluded (Fig. 1). In addition, the 25
ndividuals in the standard group who received ezetimibe
ere excluded because their different lipid goals when
ompared with those of the aggressive group confounded
he analysis. However, their inclusion did not significantly
ffect any of the comparisons shown. Including these
ndividuals, change in CIMT in the standard group at 36
onths was 0.041 mm (vs. 0.039 mm excluding them);
hange in LDL-C was 1.5 mg/dl (vs. 0.9 mg/dl excluding
hem). For all analyses, the aggressive group was divided
nto 2 subgroups: 1 group composed of patients receiving
zetimibe and 1 group composed of patients who were not
Figure 1 The SANDS Trial Participant Flow Diagram
The flow chart shows how participants were chosen and assigned to groups in the
CVD  cardiovascular disease; IMT  intima-media thickness; LDL-C  low-densiteceiving ezetimibe. Variables of interest at baseline and 36 ronths in each aggressive subgroup were compared with
he standard group as well as with each other. The changes
n these variables during the study period were tested using
-sided F and chi-square tests. A Bonferroni adjustment
as applied for multiple comparisons. To assess the effect of
reatment, the changes in the carotid measures (CIMT
ean and plaque score) were computed for each group and
he differences in changes at 36 months across groups were
ompared using Bonferroni adjusted F tests. Change in
IMT was categorized into 2 possible outcomes (de-
reased/no change vs. increased), and logistic regression
nalyses adjusting for relevant variables were conducted to
est for differences between the ezetimibe and nonezetimibe
ggressive subgroups and between the aggressive subgroups
nd the standard treatment group.
esults
ltogether, 427 SANDS participants fulfilled the inclusion
riteria for the secondary analysis, 204 in the standard
reatment group and 223 in the aggressive group (154 who
S trial.
rotein cholesterol; SBP  systolic blood pressure; TG  triglyceride.SAND
y lipopeceived statin alone and 69 who received statin plus
e
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December 16/23, 2008:2198–205 Ezetimibe in Type 2 Diabeteszetimibe). Median duration of ezetimibe therapy was 21
onths. Baseline characteristics of these subgroups are
ompared in Tables 1 and 2. In Table 2, significant
ubgroup differences in the mean change values are indi-
ated by superscripts in the standard-group column. The
ubgroups were comparable with regard to age, gender mix,
iabetes therapy, aspirin use, smoking status, and renal
unction (Table 1). Similar infrequent use of fibrates, fish
il, and niacin was seen among all of the subgroups. The
ast majority in all 3 subgroups were receiving oral hypo-
lycemic medication (Table 1). The ezetimibe subgroup,
owever, had significantly lower SBP (vs. no ezetimibe,
 0.007; vs. standard, p  0.0004) and diastolic BP (vs.
o ezetimibe, p  0.02; vs. standard, p  0.004) at
aseline than the other 2 subgroups.
ntervention. During the 36-month follow-up, no signif-
cant changes in body mass index or A1c levels were
bserved in any subgroup (Table 2). As anticipated, total
holesterol, LDL-C, and non–HDL-C were reduced sub-
tantially and to a nearly identical extent in both aggressive
ubgroups but not in the standard subgroup. Both LDL-C
nd non–HDL-C, however, averaged 10 mg/dl higher at
ollow-up in the aggressive subgroup using ezetimibe than
n the aggressive subgroup using statin alone (p  0.02),
rimarily reflecting higher baseline values. As designed,
oth LDL-C and non–HDL-C were significantly lower at
6 months in both aggressive subgroups than in the stan-
ard subgroup. Similar small increases in HDL-C occurred
n all 3 subgroups, and there were greater decreases in
riglycerides in the 2 aggressive subgroups. Serum
-reactive protein decreased similarly (24% to 26%) in the
Baseline Characteristics of the SANDS Participa
Table 1 Baseline Characteristics of the SAN
Standard Grou
(n  204)
Age, yrs 57 (56–58)
Women 138 (68)
Diabetes therapy
Lifestyle 23 (12)
Oral hypoglycemic 117 (64)
Insulin 13 (7)
Insulin plus oral 31 (17)
Lipid medications
Statins* 75 (37)
Fibrates* 10 (5)
Niacin* 2 (1)
Fish oil* 2 (1)
eGFR, n (S: 199, E: 68; E: 150) 87.7 (84–91)
Smoker 37 (18)
Aspirin (80 mg) 154 (68)
Values are n (%) or mean (95% confidence interval) unless otherwise
variance F test was used for continuous variables. The sample size for th
IMT mean measurement. The standard group excluded 25 patients w
CI  confidence interval; eGFR  estimated glomerular filtratio
intima-media thickness; S  standard group; SANDS  Stop Atheroscggressive groups but increased by 11% in the standard aubgroup (p  0.05). As anticipated, BP was reduced more
n both aggressive subgroups than in the standard subgroup;
ithin the aggressive group, SBP reduction was slightly
reater in the nonezetimibe than the ezetimibe subgroup.
dverse events thought to be related to lipid lowering drugs
ccurred in similar modest proportions (14% to 18%) in all
subgroups.
IMT. Baseline and 36-month values for CIMT and
laque score, as well as changes from baseline, are detailed
n Table 3. We found that CIMT progressed in the
tandard group and regressed in both aggressive subgroups;
t 36 months, the aggressive subgroups significantly differed
rom the standard subgroup (p  0.001). Plaque score was
imilar at baseline, with similar modest increases at 36
onths in all 3 subgroups. Figure 2 compares the propor-
ion of patients in the 3 subgroups who experienced an
ncrease in CIMT 0.01 mm from baseline to 36 months
ersus no change or a decline in CIMT. Nearly identical
roportions in the 2 aggressive subgroups (62% ezetimibe
s. 61% no ezetimibe) demonstrated no change or a decrease
n CIMT during follow-up, compared with 39% in the
tandard subgroup (p  0.0001). We found that CV events
ccurred in 16 individuals, 3.5%, 5.8%, and 3.3% of persons
n the standard, aggressive with ezetimibe, and aggressive
ithout ezetimibe subgroups, respectively (p  0.62).
In a logistic regression analysis of the categorical change
n CIMT mean over 36 months (decrease or same vs.
ncrease) that included indicator variables for the ezetimibe
nd nonezetimibe subgroups—baseline age; CIMT; body
ass index; and change in LDL-C, HDL-C, and SBP—
he ezetimibe and nonezetimibe subgroups did not differ
articipants
Aggressive Group (n  223)
p Value
Ezetimibe
(n  69)
No Ezetimibe
(n  154)
55 (53–57) 57 (55–58) 0.20
41 (59) 106 (69) 0.36
3 (4) 13 (9)
40 (59) 100 (66) 0.20
10 (15) 11 (7)
15 (22) 27 (18)
30 (44) 44 (29) 0.07
5 (7) 6 (4) 0.54
0 0 0.66
0 2 (1) 1.00
93.4 (88–99) 89.5 (86–93) 0.25
14 (20) 32 (21) 0.81
49 (71) 111 (72) 0.78
d. Chi-square test was used for categorical variables and analysis of
line characteristics was determined by the available data on 36-month
on ezetimibe. *Before randomization.
E  ezetimibe subgroup; E  no-ezetimibe subgroup; IMT 
in Native Diabetics Study.nts
DS P
p
indicate
e base
ho werend were both more likely to experience a decrease in
se
lin
e
an
d
3
6
-M
on
th
C
ha
ng
es
in
B
P
,
Li
pi
ds
,
an
d
O
th
er
R
el
ev
an
t
V
ar
ia
bl
es
ab
le
2
B
as
el
in
e
an
d
3
6
-M
on
th
C
ha
ng
es
in
B
P
,
Li
pi
ds
,
an
d
O
th
er
R
el
ev
an
t
V
ar
ia
bl
es
B
as
el
in
e
36
M
on
th
s
M
ea
n
C
ha
ng
e
at
36
M
on
th
s
p
Va
lu
e
(M
ea
n
C
ha
ng
e)
St
an
da
rd
G
ro
up
(S
)
Ez
et
im
ib
e
G
ro
up
(E

)
N
o
Ez
et
im
ib
e
G
ro
up
(E

)
St
an
da
rd
G
ro
up
(S
)
Ez
et
im
ib
e
G
ro
up
(E

)
N
o
Ez
et
im
ib
e
G
ro
up
(E

)
St
an
da
rd
G
ro
up
(S
)
Ez
et
im
ib
e
G
ro
up
(E

)
N
o
Ez
et
im
ib
e
G
ro
up
(E

)
ei
gh
t,
kg
89
*
(8
6
to
91
)
95
(9
0
to
10
0)
89
(8
6
to
92
)
91
(8
8
to
94
)
95
(9
0
to
99
)
90
(8
7
to
94
)
1.
6
(
0.
2
to
3.
1)

0.
7
(
2.
6
to
1.
3)
1.
3
(
0.
8
to
3.
4)
0.
32
M
I,
kg
/m
2
33
(3
2
to
34
)
35
(3
3
to
37
)
33
(3
2
to
34
)
34
(3
3
to
35
)
35
(3
3
to
36
)
34
(3
3
to
35
)
0.
7
(
0.
1
to
1.
2)

0.
2
(
0.
1
to
0.
5)
0.
5
(
0.
3
to
1.
3)
0.
33
ys
to
lic
BP
,
m
m
H
g
13
1*
(1
29
to
13
3)
12
4
(1
21
to
12
7)
13
0
(1
27
to
13
2)
12
9*
†
(1
28
to
13
0)
11
5
(1
13
to
11
7)
11
7
(1
15
to
11
9)

2.
4*
†
(
5
to
0)

9
(
12
to

6)

13
(
15
to

10
)
0.
00
01
ia
st
ol
ic
BP
,
m
m
H
g
75
*
(7
4
to
77
)
71
(6
9
to
74
)
75
(7
3
to
76
)
73
*†
(7
2
to
74
)
66
(6
4
to
68
)
67
(6
6
to
69
)

2†
(
3
to

1)

5
(
7
to
3)

7
(
9
to

6)
0.
00
01
ta
lC
,m
g/
dl
18
3
(1
78
to
18
7)
18
7
(1
79
to
19
5)
18
1
(1
76
to
18
7)
18
5*
†
(1
81
to
18
8)
15
6‡
(1
48
to
16
3)
14
6
(1
42
to
15
1)
2*
†
(
3
to
7.
1)

31
(
40
to

22
)

34
(
40
to

28
)
0.
00
01
L-
C,
m
g/
dl
10
2
(9
8
to
10
6)
10
8
(1
01
to
11
6)
10
1
(9
7
to
10
6)
10
3*
†
(1
00
to
10
5)
78
‡
(7
2
to
84
)
68
(6
5
to
72
)
0.
9*
†
(
3.
6
to
5.
4)

31
.1
(
36
.7
to

23
)

32
.3
(
38
to

26
.6
)
0.
00
01
D
L-
C,
m
g/
dl
46
(4
4
to
48
)
46
(4
2
to
49
)
46
(4
4
to
48
)
49
(4
7
to
50
)
48
(4
6
to
51
)
49
(4
6
to
51
)
2.
7
(1
.3
to
4.
2)
2.
7
(0
.7
to
4.
7)
2.
5
(1
to
4.
1)
0.
98
7
ta
lC
/H
D
L-
C,
m
g/
dl
4.
2
(4
.0
to
4.
3)
4.
4
(4
.1
to
4.
7)
4.
2
(4
to
4.
3)
4.
0*
†
(3
.9
to
4.
1)
3.
4
(3
.1
to
3.
6)
3.
2
(3
.0
to
3.
4)

0.
2*
†
(
0.
3
to

0.
0.
1)

1.
0
(
1.
3
to

0.
7)

0.
9
(
1.
1
to

0.
7)
0.
00
01
on
-H
D
L-
C,
m
g/
dl
13
7
(1
33
to
14
1)
14
1
(1
33
to
15
0)
13
5
(1
30
to
14
0)
13
6*
†
(1
33
to
13
9)
10
7
(1
00
to
11
5)
98
(9
3
to
10
2)

0.
7*
†
(
5.
7
to
4.
3)

34
.0
(
43
to

25
)

36
.6
(
43
to

30
)
0.
00
01
ig
ly
ce
rid
es
m
g/
dl
16
4
(1
40
to
17
1)
15
4
(1
39
to
17
1)
15
9
(1
48
to
17
1)
15
7*
†
(1
50
to
16
5)
13
6
(1
23
to
15
0)
13
8
(1
30
to
15
0)

6%
(
11
to

0.
0)

12
%
(
20
to

3)

15
%
(
21
to

8%
)
0.
11
1c
,%
7.
9
(7
.6
to
8.
2)
8.
3
(7
.8
to
8.
8)
8.
1
(7
.8
to
8.
4)
8.
0*
(7
.7
to
8.
2)
8.
7
(8
.2
to
9.
3)
8.
1
(7
.7
to
8.
4)
0.
4
(
0.
3
to
4)
0.
4
(
0.
1
to
0.
9)

0.
04
(
0.
4
to
0.
3)
0.
38
R
P,
m
g/
dl
2.
80
(2
.4
to
3.
3)
3.
25
(2
.5
to
4.
3)
2.
58
(2
.1
to
3.
2)
3.
3†
(2
.8
to
3.
9)
2.
96
(2
.1
to
4.
2)
1.
99
(1
.6
to
2.
5)

11
%
†
(
5
to
26
)

24
%
(
47
to

1%
)

26
%
(
47
to

4%
)
0.
00
8
es
ar
e
m
ea
n
(9
5
%
co
nfi
de
nc
e
in
te
rv
al
).
Th
e
p
va
lu
es
w
er
e
de
te
rm
in
ed
us
in
g
th
e
A
N
O
VA
F
te
st
.T
ri
gl
yc
er
id
es
an
d
C
R
P
w
er
e
lo
g-
tr
an
sf
or
m
ed
.T
he
m
ea
ns
pr
es
en
te
d
ar
e
ex
po
ne
nt
ia
l(
m
ea
n)
of
th
e
lo
ga
ri
th
m
ic
va
ri
ab
le
s.
Th
e
di
ff
er
en
ce
s
of
th
e
2
lo
ga
ri
th
m
ic
va
ri
ab
le
s
in
di
ca
te
n
(%
)
ch
an
ge
s
at
3
6
m
on
th
s
fo
r
ea
ch
gr
ou
p.
S
am
pl
e
si
ze
fo
r
ba
se
lin
e
an
d
3
6
m
on
th
s
m
ay
no
t
be
eq
ua
l.
Th
er
ef
or
e,
th
e
m
ea
n
ch
an
ge
s
ap
pl
y
to
th
e
sa
m
pl
e
w
he
re
bo
th
m
ea
su
re
s
ex
is
t.
*S
ig
ni
fic
an
t
di
ff
er
en
ce
be
tw
ee
n
S
an
d
E
.†
S
ig
ni
fic
an
t
di
ff
er
en
ce
be
tw
ee
n
S
an
d
(b
as
ed
on
lo
ga
ri
th
m
of
C
R
P
).
‡
S
ig
ni
fic
an
t
di
ff
er
en
ce
be
tw
ee
n
E
an
d
E
.3
6
-m
on
th
lip
id
va
ri
ab
le
s
ar
e
ba
se
d
on
th
e
av
er
ag
e
of
2
4
-,
3
0
-,
an
d
3
6
-m
on
th
ob
se
rv
at
io
ns
.p
va
lu
es
ar
e
ba
se
d
on
th
e
an
al
ys
is
of
va
ri
an
ce
of
th
e
m
ea
n
ch
an
ge
m
ea
su
re
s
co
m
pa
ri
ng
th
e
st
an
da
rd
p
to
E
an
d
E
gr
ou
ps
.A
B
on
fe
rr
on
ia
dj
us
tm
en
t
w
as
m
ad
e
to
th
e
si
gn
ifi
ca
nt
ly
di
ff
er
en
t
pa
ir
s.
M
I
bo
dy
m
as
s
in
de
x;
B
P

bl
oo
d
pr
es
su
re
;C

ch
ol
es
te
ro
l;
C
R
P

C
-r
ea
ct
iv
e
pr
ot
ei
n;
H
D
L

hi
gh
-d
en
si
ty
lip
op
ro
te
in
;L
D
L

lo
w
-d
en
si
ty
lip
op
ro
te
in
;o
th
er
ab
br
ev
ia
tio
ns
as
in
Ta
bl
e
1
.
2202 Fleg et al. JACC Vol. 52, No. 25, 2008
Ezetimibe in Type 2 Diabetes December 16/23, 2008:2198–205B
a T W B S D To LD H To N Tr A C
Va
lu
m
ea
E gr
ou B
C
o
O
(
c
a
D
I
w
a
L
r
g
a
m
e
w
r
g
b
d
w
T
a
r
a
5
t
e
r
l
A
(
a
t
e
t
h
i
m
p
r
B
C
2203JACC Vol. 52, No. 25, 2008 Fleg et al.
December 16/23, 2008:2198–205 Ezetimibe in Type 2 DiabetesIMT than the standard subgroup (ezetimibe vs. standard,
dds ratio [OR]: 2.30, p 0.009; no ezetimibe vs. standard,
R: 2.07, p 0.003). In this model, higher baseline CIMT
p  0.0001) and changes in LDL-C (p  0.06) were
orrelated with a greater reduction in CIMT. Baseline SBP
nd change in SBP did not correlate with change in CIMT.
iscussion
n the SANDS cohort, which was composed of persons
ith type 2 diabetes with baseline LDL-C 100 mg/dl,
aseline and Follow-Up Carotid Measures
Table 3 Baseline and Follow-Up Carotid Measures
Standard Group
(n  204)
Aggres
Mean (95% CI)
Ezetimibe Group (E)
Mean (95% CI)
CIMT, mm
Baseline 0.794 (0.77 to 0.82) 0.819 (0.77 to 0.86)
18 months 0.803 (0.78 to 0.82) 0.815 (0.78 to 0.86)
36 months 0.833 (0.81 to 0.86) 0.794 (0.75 to 0.84)
Mean change, 18 months 0.009 (0.01 to 0.03) 0.006 (0.03 to 0.02)
Mean change, 36 months 0.039 (0.02 to 0.06) 0.025 (0.05 to 0.003)
Plaque score
Baseline 1.83 (1.6 to 2.1) 1.93 (1.5 to 2.3)
18 months 2.02 (1.8 to 2.2) 2.10 (1.7 to 2.5)
36 months 2.33 (2.1 to 2.6) 2.35 (1.9 to 2.8)
Mean change, 18 months 0.18 (0.04 to 0.3) 0.17 (0.04 to 0.4)
Mean change, 36 months 0.51 (0.4 to 0.7) 0.42 (0.1 to 0.7)
IMT  carotid artery intima-media thickness; other abbreviations as in Table 1.
Figure 2 Categorical Change in CIMT in SANDS Subgroups
Numbers represent percentages of participants who experienced a decrease or
no change (open bars) in common carotid artery intima-media thickness (CIMT)
0.01 mm versus an increase (solid bars). The majority of both aggressive
subgroups experienced a decline or no change in IMT, whereas the majority of
the standard group showed an increase (p  0.0001). E  statin plus
ezetimibe; E  statin alone.mpproximately one-third of those targeted to an aggressive
DL-C goal of 70 mg/dl and non–HDL-C 100 mg/dl
equired ezetimibe in addition to statins to reach these
oals. Similar reductions in LDL-C and non–HDL-C were
ccompanied by a similar regression in CIMT over 36
onths in the aggressive target subgroups (0.025 mm in
zetimibe plus statin vs. 0.012 mm in nonezetimibe),
hereas CIMT increased (0.039 mm) in the group
andomized to standard targets. In a multivariate model,
reater reduction in LDL-C and non–HDL-C, higher
aseline CIMT, and younger age correlated with a greater
ecrease in CIMT, whereas treatment with ezetimibe versus
ithout ezetimibe made no independent contribution.
hus, comparable LDL-C and non–HDL-C lowering
ccomplished with statins plus ezetimibe versus statins alone
esulted in similar benefit on CIMT. There were no serious
dverse events related to lipid drugs in the trial. There were
cases of cancer: 3 in the nonezetimibe subgroup and 2 in
he standard group.
Since its introduction into clinical practice in 2002,
zetimibe has become the primary adjunct to statins in
educing elevated LDL-C (1,2). Similar to other LDL-C
owering drugs, its approval by the U.S. Food and Drug
dministration was based upon its ability to reduce LDL-C
1). Only 1 completed clinical trial (the SEAS [Simvastatin
nd Ezetimibe in Aortic Stenosis] trial) (13) has examined
he ability of ezetimibe combined with statins to reduce CV
vents; it showed a 22% reduction compared with placebo
reatment.
In the ENHANCE trial (3), of 720 patients with familial
ypercholesterolemia, no statistically significant difference
n the primary end point of mean increase in CIMT over 24
onths was seen between the statin alone and the statin
lus ezetimibe arms (p  0.29), despite a 58% versus 41%
eduction in LDL-C with combination therapy versus statin
roup (n  223)
Bonferroni Adjusted
zetimibe Group (E)
Mean (95% CI)
F Test
(p Value)
Group
Difference
(p Value)
E vs. E
Group
Difference
(p Value)
E vs. S
Group
Difference
(p Value)
E vs. S
.813 (0.78 to 0.84) 0.46
.810 (0.78 to 0.84) 0.84
.801 (0.77 to 0.83) 0.17
.005 (0.02 to 0.014) 0.48
.012 (0.03 to 0.008) 0.0001 0.01 (0.999) 0.06 (0.001) 0.05 (0.001)
1.88 (1.6 to 2.1) 0.89
2.11 (1.9 to 2.4) 0.84
2.49 (2.2 to 2.8) 0.65
0.21 (0.06 to 0.4) 0.94
0.61 (0.4 to 0.8) 0.50sive G
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t
i
e
s
E
r
t
p
i
C
d
h
c
c
f
c
t
fi
e
L
n
s
c
l
b
m
L
C
t
p
r
s
A
s
a
e
e
r
L
w
i
h
s
i
b
r
m
C
S
y
w
b
C
b
a
i
w
W
e
m
a
w
m
g
t
F
w
n
C
T
t
n

o
r
s
p
m
t
t
o
t
L
A
T
S
f
w
a
R
M
v
R
2204 Fleg et al. JACC Vol. 52, No. 25, 2008
Ezetimibe in Type 2 Diabetes December 16/23, 2008:2198–205ions, including the high baseline LDL-C levels of partic-
pants, high prevalence of prior statin therapy, lower than
xpected baseline CIMT, short follow-up, and lack of
tatistically significant primary or secondary outcomes, the
NHANCE study has stimulated controversy and concern
egarding the clinical utility of ezetimibe (3). In addition,
he report of increased CV morbidity and mortality in
atients receiving the cholesterol ester transport protein
nhibitor torcetrapib plus high-dose statin compared with
V morbidity and mortality of those receiving statin alone,
espite marked increases in HDL-C in the former group,
as raised concern that achieving apparently beneficial
hanges in serum lipid levels may not necessarily improve
linical outcomes (14). The ENHANCE findings have
urther fueled this controversy.
In contrast to the ENHANCE trial, the findings in the
urrent secondary analysis of the SANDS trial suggest that
he combination of ezetimibe plus statin, despite higher
nal level of LDL-C, has essentially an identical beneficial
ffect on CIMT as statin alone, for a similar change in
DL-C and non–HDL-C. Although the SANDS trial was
ot a randomized comparison of these therapies, several
trengths of the present analysis should be noted. As
ontrasted with the markedly elevated baseline LDL-C
evels of 319 mg/dl in ENHANCE participants, the mild
aseline elevation of LDL-C levels in the SANDS trial are
ore representative of the majority of patients requiring
DL-C lowering drugs. Additionally, the mean baseline
IMT of 0.81 mm in SANDS participants was substan-
ially greater than the value of 0.69 mm in ENHANCE
articipants, providing perhaps more opportunity to detect
egression in CIMT. The CASHMERE (Carotid Atorva-
tatin Study In Hyperlipidemic Post-Menopausal Women:
Randomized Evaluation of Atorvastatin, Versus Placebo)
tudy (15), another study where baseline CIMTs were low,
lso showed no effect of statin on CIMT. Another differ-
nce from the ENHANCE trial is our sequential use of
zetimibe after high-dose statin therapy failed to adequately
educe LDL-C or was limited by side effects. Indeed, the
DL-C reductions in the aggressive subgroups with or
ithout ezetimibe were nearly identical, as were the declines
n CIMT. Mean LDL-C and non–HDL-C were slightly
igher at both baseline and follow-up in the ezetimibe
ubgroup, although the change in LDL-C was nearly
dentical to the subgroup receiving statin alone. The higher
aseline LDL-C and non–HDL-C levels in the subgroup
equiring ezetimibe, although not statistically significant,
ight be anticipated; nevertheless, similar improvements in
IMT were observed in the 2 aggressive subgroups.
tudy limitations. Certain limitations of the present anal-
sis must be recognized. Our sample size was modest and
as not powered to detect a difference in clinical events
etween treatment groups. Thus, the primary outcome was
IMT, an index of atherosclerotic progression that has
een used in multiple modest sized trials of lipid-altering
gents (16,17). Second, this was not a randomized compar-son of statin plus ezetimibe versus statin alone; thus, there
ere differences in characteristics between these subgroups.
e found that SBP averaged 6 mm Hg lower in the
zetimibe subgroup at baseline, and the decline in SBP at 36
onths was 4 mm Hg less in this group than in the
ggressive subgroup not receiving this drug; similar trends
ere observed for diastolic BP. Although this difference
ay have biased the outcomes against the ezetimibe sub-
roup, SBP change did not significantly influence CIMT in
he main SANDS trial or in our multivariate analysis.
inally, the SANDS trial was limited to American Indians
ith diabetes; similar data in more diverse populations are
eeded.
onclusions
he findings from this secondary analysis of the SANDS
rial suggest that for a similar extent of LDL-C and
on–HDL-C lowering to respective targets of 70 and
100 mg/dl, a nearly identical regression in carotid IMT
ccurs in patients with type 2 diabetes who achieve similar
eductions in these lipid levels from a statin alone versus
tatin plus ezetimibe; in contrast, CIMT increased in
atients titrated to a conventional LDL-C target of 100
g/dl. Whether addition of ezetimibe to aggressive statin
herapy will translate into lower CV event rates in popula-
ions without prior CV events must await the results of
ngoing trials. In the interim, ezetimibe remains a viable
herapeutic option for patients who fail to reach their
DL-C target on a statin alone.
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